This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Teva Pharmaceutical Industries Ltd (TEVA)

NYSE: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) 3.04B 1.25B 1.91B 2.77B
Operating Gains/Losses 1.00M 18.00M -3.00M -207.00M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 710.00M 85.00M 936.00M 704.00M
(Increase) Decrease in Inventories 230.00M 399.00M -449.00M -410.00M
(Increase) Decrease In Other Current Assets -36.00M 106.00M -54.00M -240.00M
(Decrease) Increase In Payables -614.00M 378.00M -19.00M 543.00M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 0.00 0.00 0.00 0.00
Other Non-Cash Items 512.00M 736.00M 1.23B 407.00M
Net Cash From Continuing Operations 5.13B 3.24B 4.57B 4.13B
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 5.13B 3.24B 4.57B 4.13B
Sale of Property, Plant & Equipment 196.00M 187.00M 264.00M 279.00M
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -929.00M -1.03B -1.10B -1.05B
Acquisitions -363.00M -39.00M 0.00 -6.56B
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities -30.00M -104.00M -93.00M -49.00M
Cash Provided by Financing Activities
Net Cash From Investing Activities -1.45B -1.15B -1.13B -7.60B
Issuance of Debt 0.00 338.00M 1.24B 6.72B
Cash Used for Financing Activities
Issuance of Capital Stock 514.00M 91.00M 14.00M 71.00M
Repayment of Long-Term Debt -839.00M -3.13B -2.21B -1.56B
Repurchase of Capital Stock -500.00M -497.00M -1.16B -899.00M
Payment of Cash Dividends -1.16B -1.09B -855.00M -800.00M
Other Financing Charges, Net -394.00M 407.00M 1.30B -194.00M
Net Cash From Financing Activities -2.38B -3.88B -1.68B 3.34B
Effect of Exchange Rate Changes -114.00M -48.00M 23.00M -21.00M
Net Change in Cash & Cash Equivalents 1.19B -1.84B 1.78B -152.00M

TEVA Teva Pharmaceutical Industries Ltd

Analysts Ratings for TEVA

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 12 12 11 11
Moderate Buy 1 1 1 1
Hold 9 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

TEVA Chatter

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs